Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018133 (
graft-versus-host disease
)
18,032
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The butyric acid derivative, 2-(4-morpholynl) ethyl butyrate hydrochloride (
MEB
), has been reported to induce antigen-specific T cell unresponsiveness and to block T cell-mediated
graft-versus-host disease
. As a potential therapeutic agent, it was important to determine the effects of
MEB
on other cells that contribute to immunopathology. Accordingly, we tested the effects of
MEB
on macrophage functions.
MEB
did not affect macrophage viability, phagocytic activity, or the activation-induced up-regulation of molecules associated with antigen presentation: MHC-II, CD86, CD40, or ICAM-1. However,
MEB
potently inhibited activation-induced production of inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), IL-6, chemokine CCL2 and nitric oxide (NO).
MEB
inhibited the induction of NO synthase (NOS2), which is necessary for inducible NO, and inhibited nuclear translocation of NFkappaB, suggesting that
MEB
interferes with the signaling pathway involved in NOS2 induction. Thus, while inducing specific T cell unresponsiveness,
MEB
also exerts anti-inflammatory activity by acting on macrophages to suppress production of cytokines and NO.
...
PMID:Macrophage production of inflammatory mediators is potently inhibited by a butyric acid derivative demonstrated to inactivate antigen-stimulated T cells. 1525 Nov 19